Table 2 Characteristics of patient study groups
No change of DMARD | Change of DMARD | Reason for change | ||
|---|---|---|---|---|
Adverse drug reaction | Lack of efficacy | |||
N | 356 | 410 | 139 | 230 |
Female | 65% | 72% * | 71% | 72% |
Age (yrs) | 58 (47–68) | 56 (46–66) | 60 (50–70) | 54 (44–63) ** |
BMI (kg/m2) | 26.4 (23.9 - 30.1) | 26.9 (23.7 - 30.8) | 26.6 (23.8 - 30.5) | 27.2 (23.9 - 31.2) |
Ever smoked | 57% | 65% * | 66% | 65% |
Current smoker | 35% | 39% | 39% | 37% |
Symptom duration (mo) | 6 (4–12) | 6 (4–12) | 5 (3–10) | 6 (3–13) |
Erosions | 47% | 26% | 23% | 28% |
HAQ (0–3) | 1.0 (0.4 - 0.6) | 1.4 (0.8 - 1.9) ** | 1.3 (0.6 - 1.8) * | 1.4 (0.8 - 1.9) ** |
>4 of 1987 ACR criteria | 51% | 59% * | 53% | 65% ** |
Seropositive | 62% | 61% | 54% | 64% |
Extra-articular disease | 11% | 20% ** | 15% | 24% ** |
Co-morbidity | 44% | 50% | 56% * | 49% |
DAS28 | 4.6 (3.6 - 5.7) | 5.1 (4.0 - 6.1) ** | 4.8 (3.5 - 5.7) | 5.4 (4.1 - 6.2) ** |
DAS28-P (0–1) | 0.41 (0.32 - 0.47) | 0.43 (0.35 - 0.50) ** | 0.42 (0.32 - 0.50) | 0.43 (0.37 - 0.50) ** |
SF36-Bodily pain (0–100) | 41 (31–62) | 32 (22–51) ** | 41 (22–62) * | 31 (21–42) ** |
SF36-Mental Health (0–100) | 68 (52–80) | 60 (48–72) ** | 60 (48–72) ** | 56 (48–70) ** |
Steroid at baseline | 17% | 16% | 14% | 16% |
Sulphasalazine monotherapy | 27% | 43% | 59% | 33% |
Methotrexate monotherapy | 53% | 36% | 23% | 48% |
Other monotherapy | 4% | 11% | 9% | 12% |
Dual therapy | 6% | 5% | 7% | 4% |
Triple therapy | 10% | 4% | 2% | 4% |